# Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

> **NCT04002687** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 44 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** ATV-PG 1000-400 mg + AQ 612 mg

## Key facts

- **NCT ID:** NCT04002687
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2019-10-29
- **Final completion:** 2019-10-29
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002687, "Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04002687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*